Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.

Nakhla M, Nair A, Balani P, Ujjawal A, Arun Kumar P, Dasari M, Yukselen Z, Bansal K, Ganatra S, Dani SS

Cardiovascular drugs and therapy12 Sept 2024Cited by 20 (Europe PMC)

PMID39264502DOI10.1007/s10557-024-07613-wPepBankPUB-39264502

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studySafety outcome
In pharmacovigilance data, semaglutide had a reported suicidal-event ROR of 0.6 (interval 0.51-0.71; reference unspecified), alongside the source description of higher reporting than DPP4is and SGLT2is.
In plain wordsIn safety reports, the semaglutide suicidal-event reporting-ratio reference was unclear; its reported ratio conflicted with the source comparison.
Peptide
Semaglutide
Outcome
Direction not reportedSuicidal-event reporting odds ratio with unclear reference
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated
Measurements
ROR
0.6
0.51-0.71; reference unclear
Source sentences
Summary
Semaglutide [ROR = 0.60 (0.51-0.71)] and liraglutide [ROR = 0.28 (0.23-0.35)] had higher suicidal events than DPP4is and SGLT2is.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
Report a problemFND-3926450207
02HumanObservational studySafety outcome
In pharmacovigilance data, liraglutide had a reported suicidal-event ROR of 0.28 (interval 0.23-0.35; reference unspecified), alongside the source description of higher reporting than DPP4is and SGLT2is.
In plain wordsIn safety reports, the liraglutide suicidal-event reporting-ratio reference was unclear; its reported ratio conflicted with the source comparison.
Peptide
Liraglutide
Outcome
Direction not reportedSuicidal-event reporting odds ratio with unclear reference
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated
Measurements
ROR
0.28
0.23-0.35; reference unclear
Source sentences
Summary
Semaglutide [ROR = 0.60 (0.51-0.71)] and liraglutide [ROR = 0.28 (0.23-0.35)] had higher suicidal events than DPP4is and SGLT2is.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
Report a problemFND-3926450208
03HumanObservational studySafety outcome
In pharmacovigilance data, semaglutide was one of the three leading medications reported with hair loss.
In plain wordsIn safety-report data, semaglutide was one of the three leading medicines reported with hair loss.
Peptide
Semaglutide
Outcome
Not applicableHair loss reporting ranking
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated
Source sentences
Summary
GLP1-RAs were the most reported class with hair loss [ROR = 0.61 (0.60-0.64)], and semaglutide, liraglutide, and dulaglutide were the three leading medications.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
Report a problemFND-3926450211
04HumanObservational studySafety outcome
In pharmacovigilance data, liraglutide was one of the three leading medications reported with hair loss.
In plain wordsIn safety-report data, liraglutide was one of the three leading medicines reported with hair loss.
Peptide
Liraglutide
Outcome
Not applicableHair loss reporting ranking
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated
Source sentences
Summary
GLP1-RAs were the most reported class with hair loss [ROR = 0.61 (0.60-0.64)], and semaglutide, liraglutide, and dulaglutide were the three leading medications.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
Report a problemFND-3926450212
05HumanObservational studySafety outcome
In pharmacovigilance reports, the source describes higher suicidal-event reporting with semaglutide than DPP4 inhibitors; no unambiguous contrast-specific coefficient was provided.
In plain wordsIn safety reports, semaglutide had higher suicidal-event reporting than DPP4 inhibitors; the comparison estimate was unclear.
Peptide
Semaglutide
Outcome
IncreaseSuicidal-event reporting comparison
Study
n: not reported in source
Comparator
DPP4 inhibitors
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide [ROR = 0.60 (0.51-0.71)] and liraglutide [ROR = 0.28 (0.23-0.35)] had higher suicidal events than DPP4is and SGLT2is.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
Report a problemFND-3926450213
06HumanObservational studySafety outcome
In pharmacovigilance reports, the source describes higher suicidal-event reporting with semaglutide than SGLT2 inhibitors; no unambiguous contrast-specific coefficient was provided.
In plain wordsIn safety reports, semaglutide had higher suicidal-event reporting than SGLT2 inhibitors; the comparison estimate was unclear.
Peptide
Semaglutide
Outcome
IncreaseSuicidal-event reporting comparison
Study
n: not reported in source
Comparator
SGLT2 inhibitors
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide [ROR = 0.60 (0.51-0.71)] and liraglutide [ROR = 0.28 (0.23-0.35)] had higher suicidal events than DPP4is and SGLT2is.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
Report a problemFND-3926450214
07HumanObservational studySafety outcome
In pharmacovigilance reports, the source describes higher suicidal-event reporting with liraglutide than DPP4 inhibitors; no unambiguous contrast-specific coefficient was provided.
In plain wordsIn safety reports, liraglutide had higher suicidal-event reporting than DPP4 inhibitors; the comparison estimate was unclear.
Peptide
Liraglutide
Outcome
IncreaseSuicidal-event reporting comparison
Study
n: not reported in source
Comparator
DPP4 inhibitors
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide [ROR = 0.60 (0.51-0.71)] and liraglutide [ROR = 0.28 (0.23-0.35)] had higher suicidal events than DPP4is and SGLT2is.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
Report a problemFND-3926450217
08HumanObservational studySafety outcome
In pharmacovigilance reports, the source describes higher suicidal-event reporting with liraglutide than SGLT2 inhibitors; no unambiguous contrast-specific coefficient was provided.
In plain wordsIn safety reports, liraglutide had higher suicidal-event reporting than SGLT2 inhibitors; the comparison estimate was unclear.
Peptide
Liraglutide
Outcome
IncreaseSuicidal-event reporting comparison
Study
n: not reported in source
Comparator
SGLT2 inhibitors
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide [ROR = 0.60 (0.51-0.71)] and liraglutide [ROR = 0.28 (0.23-0.35)] had higher suicidal events than DPP4is and SGLT2is.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
Report a problemFND-3926450218

Studies that did not test the peptide alone12

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

09HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pharmacovigilance data, pooled GLP-1RAs including semaglutide did not meet the study's positive-signal criterion for suicide.
In plain wordsIn safety-report data, pooled GLP-1 medicines including semaglutide did not meet the study's positive-signal rule for suicide.
Peptide
Semaglutide
Outcome
Not applicablePositive signal for suicide risk
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Source sentences
Summary
No positive signals were observed between GLP1-RAs and either suicide, hair loss, or aspiration risks.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3926450201
10HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pharmacovigilance data, pooled GLP-1RAs including liraglutide did not meet the study's positive-signal criterion for suicide.
In plain wordsIn safety-report data, pooled GLP-1 medicines including liraglutide did not meet the study's positive-signal rule for suicide.
Peptide
Liraglutide
Outcome
Not applicablePositive signal for suicide risk
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Source sentences
Summary
No positive signals were observed between GLP1-RAs and either suicide, hair loss, or aspiration risks.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3926450202
11HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pharmacovigilance data, pooled GLP-1RAs including semaglutide did not meet the study's positive-signal criterion for hair loss.
In plain wordsIn safety-report data, pooled GLP-1 medicines including semaglutide did not meet the study's positive-signal rule for hair loss.
Peptide
Semaglutide
Outcome
Not applicablePositive signal for hair loss risk
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
No positive signals were observed between GLP1-RAs and either suicide, hair loss, or aspiration risks.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3926450203
12HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pharmacovigilance data, pooled GLP-1RAs including liraglutide did not meet the study's positive-signal criterion for hair loss.
In plain wordsIn safety-report data, pooled GLP-1 medicines including liraglutide did not meet the study's positive-signal rule for hair loss.
Peptide
Liraglutide
Outcome
Not applicablePositive signal for hair loss risk
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
No positive signals were observed between GLP1-RAs and either suicide, hair loss, or aspiration risks.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3926450204
13HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pharmacovigilance data, pooled GLP-1RAs including semaglutide did not meet the study's positive-signal criterion for aspiration.
In plain wordsIn safety-report data, pooled GLP-1 medicines including semaglutide did not meet the study's positive-signal rule for aspiration.
Peptide
Semaglutide
Outcome
Not applicablePositive signal for aspiration risk
Study
n: not reported in source
Outcome group
Adverse events · Respiratory
Source sentences
Summary
No positive signals were observed between GLP1-RAs and either suicide, hair loss, or aspiration risks.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3926450205
14HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pharmacovigilance data, pooled GLP-1RAs including liraglutide did not meet the study's positive-signal criterion for aspiration.
In plain wordsIn safety-report data, pooled GLP-1 medicines including liraglutide did not meet the study's positive-signal rule for aspiration.
Peptide
Liraglutide
Outcome
Not applicablePositive signal for aspiration risk
Study
n: not reported in source
Outcome group
Adverse events · Respiratory
Source sentences
Summary
No positive signals were observed between GLP1-RAs and either suicide, hair loss, or aspiration risks.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3926450206
15HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pharmacovigilance data, pooled GLP-1RAs including semaglutide were the most reported class with hair loss (ROR 0.61, interval 0.60-0.64; reference and interval confidence level unspecified).
In plain wordsIn safety-report data, the GLP-1 medicine class including semaglutide was most reported for hair loss; the reporting-ratio reference was not stated.
Peptide
Semaglutide
Outcome
Not applicableHair loss reporting
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Measurements
ROR
0.61
pooled GLP-1RAs; interval 0.60-0.64; reference and confidence level unstated
Source sentences
Summary
GLP1-RAs were the most reported class with hair loss [ROR = 0.61 (0.60-0.64)], and semaglutide, liraglutide, and dulaglutide were the three leading medications.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3926450209
16HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pharmacovigilance data, pooled GLP-1RAs including liraglutide were the most reported class with hair loss (ROR 0.61, interval 0.60-0.64; reference and interval confidence level unspecified).
In plain wordsIn safety-report data, the GLP-1 medicine class including liraglutide was most reported for hair loss; the reporting-ratio reference was not stated.
Peptide
Liraglutide
Outcome
Not applicableHair loss reporting
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Measurements
ROR
0.61
pooled GLP-1RAs; interval 0.60-0.64; reference and confidence level unstated
Source sentences
Summary
GLP1-RAs were the most reported class with hair loss [ROR = 0.61 (0.60-0.64)], and semaglutide, liraglutide, and dulaglutide were the three leading medications.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3926450210
17HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pharmacovigilance reports, pooled GLP-1RAs including semaglutide ranked below the named aspiration-reporting leader Sitagliptin; no clinical-risk estimate was reported.
In plain wordsIn safety reports, pooled GLP-1 medicines including semaglutide ranked below Sitagliptin for aspiration reporting.
Peptide
Semaglutide
Outcome
Not applicableAspiration-event reporting rank
Study
n: not reported in source
Comparator
Sitagliptin
Outcome group
Adverse events · Respiratory
Source sentences
Summary
GLP1-RAs ranked lower with aspiration events, which were led by sitagliptin and DPP4is as a group.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3926450215
18HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pharmacovigilance reports, pooled GLP-1RAs including semaglutide ranked below the named aspiration-reporting leader DPP4 inhibitors as a group; no clinical-risk estimate was reported.
In plain wordsIn safety reports, pooled GLP-1 medicines including semaglutide ranked below DPP4 inhibitors as a group for aspiration reporting.
Peptide
Semaglutide
Outcome
Not applicableAspiration-event reporting rank
Study
n: not reported in source
Comparator
DPP4 inhibitors as a group
Outcome group
Adverse events · Respiratory
Source sentences
Summary
GLP1-RAs ranked lower with aspiration events, which were led by sitagliptin and DPP4is as a group.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3926450216
19HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pharmacovigilance reports, pooled GLP-1RAs including liraglutide ranked below the named aspiration-reporting leader Sitagliptin; no clinical-risk estimate was reported.
In plain wordsIn safety reports, pooled GLP-1 medicines including liraglutide ranked below Sitagliptin for aspiration reporting.
Peptide
Liraglutide
Outcome
Not applicableAspiration-event reporting rank
Study
n: not reported in source
Comparator
Sitagliptin
Outcome group
Adverse events · Respiratory
Source sentences
Summary
GLP1-RAs ranked lower with aspiration events, which were led by sitagliptin and DPP4is as a group.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3926450219
20HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pharmacovigilance reports, pooled GLP-1RAs including liraglutide ranked below the named aspiration-reporting leader DPP4 inhibitors as a group; no clinical-risk estimate was reported.
In plain wordsIn safety reports, pooled GLP-1 medicines including liraglutide ranked below DPP4 inhibitors as a group for aspiration reporting.
Peptide
Liraglutide
Outcome
Not applicableAspiration-event reporting rank
Study
n: not reported in source
Comparator
DPP4 inhibitors as a group
Outcome group
Adverse events · Respiratory
Source sentences
Summary
GLP1-RAs ranked lower with aspiration events, which were led by sitagliptin and DPP4is as a group.
4 context sentences(design, population, supporting numbers)
Summary · context
We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency…
Summary · context
OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin.
Summary · context
The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ²).
Summary · context
A positive signal was detected if PRR > 2 and χ² > 4 for any drug-event pair.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3926450220

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.